Comparison of Intradermal Injection with Mesotherapy of Botulinum Toxin Type A for Axillary Sweat Reduction: A Preliminary, Prospective, Randomized, Self-controlled Study.

BACKGROUND

Relieving botulinum toxin type A (BoNT-A) injection-related pain is important for hyperhidrosis treatment. Till now, there is no report on the comparison of BoNT-A intradermal injection (BontAintra) and BoNT-A mesotherapy (BontAmeso).

OBJECTIVES

The purpose of this study was to investigate the effect, duration of efficacy, pain, and patients' satisfaction of BontAintra and BontAmeso.

METHODS

This preliminary, prospective, randomized, self-controlled study recruited subjects expecting to reduce axillary sweat. The subjects were randomized to receive a 50 U BontAintra on the left axillae and a 50, 60, or 70 U BontAmeso on the right axillae, respectively. The axillary sweat weight and hyperhidrosis severity scale (HDSS) on 2 weeks, 1 months, 4 months, and 6 months post-treatment were measured. The pain, satisfaction, and adverse events (AEs) were compared.

RESULTS

Thirty-one subjects were enrolled. According to the axillary sweat weight and HDSS, the 70 U BontAmeso generated statistically comparable axillary sweat reduction and duration of efficacy with the 50 U BontAintra. The efficacy of 50 and 60 U BontAmeso was comparable with the 50 U BontAintra on the 2 week follow-up, and the duration of efficacy was significantly shorter. The pain ratings with three dosages of BontAmeso were significantly lower than those with BontAintra. The subjects' satisfaction ratings with BontAmeso were significantly higher than those with BontAintra. No serious AEs occurred.

CONCLUSIONS

Compared with the 50 U BontAintra, the 70 U BontAmeso generated statistically comparable axillary sweat reduction and duration of efficacy, with significantly lower treatment-associated pain and higher satisfaction.

LEVEL OF EVIDENCE IV: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .